NIH Trial Halts After Smallpox Drug Fails to Show Benefit for Mpox
A clinical trial testing a smallpox antiviral for mpox was halted after interim findings showed no efficacy in reducing lesion resolution or pain in mild to moderate cases.
A clinical trial testing a smallpox antiviral for mpox was halted after interim findings showed no efficacy in reducing lesion resolution or pain in mild to moderate cases.
A clinical trial testing a smallpox antiviral for mpox was halted after interim findings showed no efficacy in reducing lesion resolution or pain in mild to moderate cases.
Read MoreA large increase in skin bacteria in mice inoculated with the smallpox vaccine may enhance the immune response, according to a study published in Plos Pathogens.
Read MoreAccording to an article in The Scientist magazine, several high profile pathogens dominated the medical news landscape in 2014.
Read MoreUS lawmakers on Monday said they were expanding their investigation of federal biosecurity lapses including problems at the CDC that led to the mishandling of anthrax and bird flu pathogens.
Read MoreAfter a series of laboratory blunders involving anthrax, avian flu, and most recently smallpox, the CDC has temporarily suspended activity at its anthrax and flu labs until new health and safety policies are introduced.
Read MoreRespiratory therapists should be able to recognize the signs and symptoms of smallpox infection so that effective control measures can be implemented in case of a bioterrorism attack.
Read MoreSerious tactical planning for bioterrorism and other acts of mass violence has been under way since the early 1990s. Health practitioners’ skills are being honed, but questions remain.
Read MoreRespiratory care can play a significant role in the diagnosis, initial care, and follow-up care of victims of bioterrorism attacks. The opportunities for expansion of the scope of respiratory practice are legion.
Read More